What is the recommended treatment for an adolescent patient with renal cell carcinoma that has metastasized to the lungs?

Treatment of Adolescent with Metastatic Renal Cell Carcinoma to the Lungs

For an adolescent with renal cell carcinoma metastatic to the lungs, initiate systemic therapy with a combination of immune checkpoint inhibitors and VEGF-targeted therapy, specifically nivolumab plus ipilimumab for intermediate/poor-risk disease or a VEGF-TKI plus PD-1 inhibitor combination (such as cabozantinib-nivolumab or lenvatinib-pembrolizumab) for all risk groups, while considering surgical metastasectomy only if oligometastatic disease with favorable features is present.

Risk Stratification First

Before treatment selection, classify the patient using IMDC criteria (hemoglobin, calcium, Karnofsky performance status, time from diagnosis to treatment, neutrophils, platelets). This determines prognosis and guides therapy selection 1.

Surgical Considerations

Cytoreductive Nephrectomy

• Perform nephrectomy only in highly selected adolescents with good performance status, low IMDC risk (0-1 factors), and limited metastatic burden 2
• Avoid upfront nephrectomy in poor-risk patients or those with extensive metastatic disease 3
• If symptomatic primary tumor (hematuria, pain), palliative nephrectomy is indicated 3

Pulmonary Metastasectomy

Consider metastasectomy for lung metastases if:

• Solitary or easily accessible pulmonary lesions
• Long disease-free interval (≥2 years if metachronous)
• Complete resection achievable
• Good performance status 4

This approach may provide survival benefit in carefully selected patients with lung-only metastases 5, 6. However, most patients will recur even after complete resection 3.

First-Line Systemic Therapy

For Intermediate/Poor-Risk Disease (IMDC 1-6 factors):

Preferred options:

1. Nivolumab + ipilimumab - the standard of care showing OS benefit 1
2. Cabozantinib + nivolumab - demonstrated significant OS, PFS, and response rate advantages 7
3. Lenvatinib + pembrolizumab - FDA-approved with median OS not reached and 71% response rate 7

For Good-Risk Disease (IMDC 0 factors):

VEGF-targeted monotherapy remains acceptable:

• Sunitinib, pazopanib, or tivozanib 1
• However, combination therapy with VEGF-TKI plus PD-1 inhibitor is increasingly preferred across all risk groups 7

Pediatric-Specific Considerations:

While guidelines are based on adult data, case reports demonstrate that adolescents tolerate and respond to targeted therapies including sunitinib, sorafenib, bevacizumab, and everolimus 8, 9. Monitor closely for:

• Hypothyroidism (common with TKIs)
• Significant hypertension (especially with bevacizumab and sunitinib) 8
• Dose reductions frequently needed (68.8% in lenvatinib-pembrolizumab trials) 7

Subsequent-Line Therapy

After First-Line VEGF-TKI:

1. Nivolumab - demonstrated OS benefit over everolimus 1
2. Cabozantinib - showed OS and PFS improvement 1
3. If neither available: everolimus or axitinib 1

After First-Line Immunotherapy:

• Switch to VEGF-TKI (cabozantinib preferred) 1
• Alternatively: everolimus or axitinib 1

Critical Pitfalls to Avoid

1. Do not delay systemic therapy for surgery in patients with extensive metastatic disease or poor performance status - the CARMENA trial showed sunitinib alone was noninferior to nephrectomy plus sunitinib in unselected patients 3

2. Do not use traditional chemotherapy - RCC is notoriously chemoresistant. The exception is collecting duct/medullary carcinoma (rare in adolescents) which requires platinum-based regimens 1

3. Do not assume Wilms tumor - over 40% of renal tumors in teenagers are RCC, not Wilms 10. Biopsy if diagnosis uncertain, as treatment differs dramatically

4. Do not withhold immunotherapy due to age - while data are limited in adolescents, case reports show efficacy and tolerability of both TKIs and checkpoint inhibitors in this population 8, 9

Monitoring and Supportive Care

• Baseline and serial thyroid function tests
• Blood pressure monitoring (treat hypertension aggressively)
• Consider observation period before treatment only in asymptomatic patients with very indolent, low-volume disease 4
• For poor performance status patients with extensive disease, palliative care alone may be most appropriate 1

Prognosis Context

Pediatric RCC is aggressive with 50% presenting with metastases at diagnosis 11. Lung and liver are the most common metastatic sites 11. Early diagnosis when confined to kidney provides best outcomes, but with modern systemic therapy, median survival in metastatic disease ranges from 8.8 months (poor-risk) to not reached (good-risk) 3.